miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1 (original) (raw)

Access this article

Log in via an institution

Subscribe and save

• Starting from 10 chapters or articles per month
• Access and download chapters and articles from more than 300k books and 2,500 journals
• Cancel anytime View plans

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

1. Legge F, Ferrandina G, Salutari V, et al. Biological characterization of ovarian cancer: prognostic and therapeutic implications. Ann Oncol, 2005,16(Suppl 4):iv95–101
   Article PubMed Google Scholar
2. Reed NS, Sadozye AH. Role of chemotherapy in the management of epithelial ovarian cancer. Expert Rev Anticancer Ther, 2005,5(1):139–147
   Article PubMed CAS Google Scholar
3. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer, 2003,3(7):502–516
   Article PubMed CAS Google Scholar
4. Lai EC. Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet, 2002,30(4):363–364
   Article PubMed CAS Google Scholar
5. Carninci P, Kasukawa T, Katayama S, et al. The transcriptional landscape of the mammalian genome. Science, 2005,309(5740):1559–1563
   Article PubMed CAS Google Scholar
6. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell, 2005,122(1):6–7
   Article PubMed CAS Google Scholar
7. Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle, 2005,4(9):1179–1184
   Article PubMed CAS Google Scholar
8. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA, 2005,102(39):13 944–13 949
   Article CAS Google Scholar
9. Bandi N, Zbinden S, Gugger M, et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res, 2009,69(13):5553–5559
   Article PubMed CAS Google Scholar
10. Sorrentino A, Liu CG, Addario A, et al. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol, 2008,111(3):478–486
    Article PubMed CAS Google Scholar
11. Zhao JJ, Lin J, Yang H, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem, 2008,283(45):31 079–31 086
    Article CAS Google Scholar
12. Fujita Y, Kojima K, Hamada N, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun, 2008,377(1): 114–119
    Article PubMed CAS Google Scholar
13. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res, 2007,67(18): 8699–8707
    Article PubMed CAS Google Scholar
14. van Jaarsveld MT, Helleman J, Berns EM, et al. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol, 2010,42(8):1282–1290
    Article PubMed Google Scholar
15. Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther, 2010,17(8):523–531
    Article PubMed CAS Google Scholar
16. Cuconati A, Mukherjee C, Perez D, et al. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev, 2003,17(23):2922–2932
    Article PubMed CAS Google Scholar
17. Jones NA, Turner J, McIlwrath AJ, et al. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol, 1998,53(5):819–826
    PubMed CAS Google Scholar
18. Kyrgiou M, Salanti G, Pavlidis N, et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst, 2006,98(22):1655–1663
    Article PubMed CAS Google Scholar
19. Ferrandina G, Zannoni GF, Martinelli E, et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res, 2006,12(9):2774–2779
    Article PubMed CAS Google Scholar
20. Zheng T, Wang J, Chen X, et al. Role of microRNA in anticancer drug resistance. Int J Cancer, 2010,126(1):2–10
    Article PubMed CAS Google Scholar
21. Kobayashi T, Lu J, Cobb BS, et al. Dicer-dependent pathways regulate chondrocyte proliferation and differentiation. Proc Natl Acad Sci USA, 2008,105(6):1949–1954
    Article PubMed CAS Google Scholar
22. Huang Q, Gumireddy K, Schrier M, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol, 2008,10(2):202–210
    Article PubMed CAS Google Scholar
23. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res, 2008,68(2):425–433
    Article PubMed CAS Google Scholar
24. Shi XB, Xue L, Yang J, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA, 2007,104(50):19 983–19 988
    CAS Google Scholar
25. Zhou M, Liu Z, Zhao Y, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem, 2010,285(28):21496–21507
    Article PubMed CAS Google Scholar

Download references